Bionano Genomics, Inc. (BNGO)
Automate Your Wheel Strategy on BNGO
With Tiblio's Option Bot, you can configure your own wheel strategy including BNGO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BNGO
- Rev/Share 10.5657
- Book/Share 17.8872
- PB 0.2041
- Debt/Equity 0.3821
- CurrentRatio 1.7013
- ROIC -1.2164
- MktCap 12278600.0
- FreeCF/Share -16.196
- PFCF -0.2814
- PE -0.1175
- Debt/Assets 0.2348
- DivYield 0
- ROE -1.5735
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 5
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | BNGO | BTIG Research | Buy | Neutral | -- | -- | Sept. 10, 2024 |
News
Bionano Laboratories Announces a Second Category I CPT Code for OGM Established by the AMA; this one for Use in Whole Genome Analysis for Constitutional Genetic Disorders
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced that the editorial panel of the American Medical Association (AMA) established a new Category I Current Procedural Terminology (CPT®) code for the use of OGM in cytogenomic genome-wide analysis to detect structural and copy number variations related to constitutional genetic disorders. The CPT code is a key component in obtaining reimbursement for the OGM-Dx™ Postnatal Whole Genome SV and OGM-Dx™ Prenatal Whole Genome SV LDTs from …
Read More
International Consortium for Optical Genome Mapping Publishes Expert Recommendations for Integration of OGM as a Standard-of-Care Cytogenetic Assay for Diagnostic Workflows in Blood Cancers
Published: May 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced the publication in the American Journal of Hematology of expert recommendations from the International Consortium for Optical Genome Mapping (ICOGM) for the integration of OGM as a standard-of-care (SOC) cytogenetic assay for diagnostic workflows in various clinical settings. Nineteen (19) experts from the ICOGM, representing relevant multidisciplinary fields, conducted an in-depth review of the classification of hematolymphoid malignancies using the World Health Organization (WHO, 5th ed.
Read More
Study Using OGM in Neural Tube Defects Reveals Previously Unreported Variants and Candidate Genes with Potential Links to the Devastating Birth Defect
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, and GREENWOOD, S.C., March 24, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) and Greenwood Genetic Center (GGC) today announced a publication in Genome Research describing the first study to use optical genome mapping (OGM) to investigate the genetic landscape of neural tube defects (NTDs). NTDs are the most common birth defect of the central nervous system and some of the most devastating congenital conditions. Despite an expected genetic link in as many as 60-70% of cases, methods currently in use, including karyotyping (KT), chromosomal microarray (CMA) and next-generation sequencing (NGS), collectively identify pathogenic gene variants in …
Read More
About Bionano Genomics, Inc. (BNGO)
- IPO Date 2018-08-21
- Website https://www.bionanogenomics.com
- Industry Medical - Diagnostics & Research
- CEO Dr. Robert Erik Holmlin M.B.A., Ph.D.
- Employees 98